Literature DB >> 28558111

Clinical Results of Minimally Invasive Spine Stabilization for Spinal Metastases.

Hiroshi Uei, Yasuaki Tokuhashi, Masashi Oshima, Masafumi Maseda, Koji Matsumoto, Hirotoki Soma, Enshi Nakayama, Yuichiro Tachikawa.   

Abstract

The goal of the study was to evaluate minimally invasive palliative surgery and the effect of postoperative adjuvant therapy for metastatic spinal tumor with a limited vital prognosis. Of the 70 patients who underwent palliative surgery for metastatic spinal tumor at the authors' hospital between March 2012 and May 2016, thirty-three were treated with minimally invasive spine stabilization (MISt) using percutaneous pedicle screws (PPSs) and included in the current study. Of the 33 patients, 26 were men and 7 were women; mean age at surgery was 68.6 years. Intraoperatively, posterior decompression and fusion was performed in 17 (51.5%) patients and fusion only was performed in 16 (48.5%). Mean operative time was 202.5 minutes, mean intraoperative blood loss was 331.6 mL, and intraoperative blood loss was 1500 mL or greater in 2 (6.1%) patients. Median postoperative survival time determined using the Kaplan-Meier method was 11.0 months (95% confidence interval, 7.3-14.6). Regarding improvement of paralysis, neurological deficit was improved by at least 1 Frankel grade for 15 (45.5%) patients, and the number of ambulatory patients increased from 22 (66.7%) to 25 (75.8%). Postoperative adjuvant therapy included chemotherapy in 17 (51.5%) patients, radiotherapy in 21 (63.6%), and bone-modifying agent treatment in 25 (75.8%). The mean Barthel Index for activities of daily living improved from 53.5 preoperatively to 71.5 postoperatively. Discharge to home was possible for 23 (69.7%) patients. Activities of daily living for patients with metastatic spinal tumor were improved by minimally invasive palliative surgery with MISt using PPSs and postoperative adjuvant therapy. [Orthopedics. 2017; 40(4):e693-e698.]. Copyright 2017, SLACK Incorporated.

Entities:  

Mesh:

Year:  2017        PMID: 28558111     DOI: 10.3928/01477447-20170522-02

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  6 in total

1.  Comparison between minimally invasive spine stabilization with and without posterior decompression for the management of spinal metastases: a retrospective cohort study.

Authors:  Hiroshi Uei; Yasuaki Tokuhashi; Masafumi Maseda; Masahiro Nakahashi; Hirokatsu Sawada; Enshi Nakayama; Hirotoki Soma
Journal:  J Orthop Surg Res       Date:  2018-04-16       Impact factor: 2.359

2.  Clinical Results of Minimally Invasive Spine Stabilization for the Management of Metastatic Spinal Tumors Based on the Epidural Spinal Cord Compression Scale.

Authors:  Hiroshi Uei; Yasuaki Tokuhashi; Masafumi Maseda; Masahiro Nakahashi; Hirokatsu Sawada; Koji Matsumoto; Hiroyuki Miyakata; Hirotoki Soma
Journal:  Biomed Res Int       Date:  2018-11-08       Impact factor: 3.411

3.  Therapeutic Impact of Percutaneous Pedicle Screw Fixation on Palliative Surgery for Metastatic Spine Tumors.

Authors:  Hiroshi Uei; Yasuaki Tokuhashi
Journal:  Indian J Orthop       Date:  2019 Jul-Aug       Impact factor: 1.251

4.  Neurological outcome of treatment for patients with impending paralysis due to epidural spinal cord compression by metastatic spinal tumor.

Authors:  Masafumi Maseda; Hiroshi Uei; Masahiro Nakahashi; Hirokatsu Sawada; Yasuaki Tokuhashi
Journal:  J Orthop Surg Res       Date:  2019-09-03       Impact factor: 2.359

5.  Comprehensive surgical treatment strategy for spinal metastases.

Authors:  Arthur Wagner; Elena Haag; Ann-Kathrin Joerger; Philipp Jost; Stephanie E Combs; Maria Wostrack; Jens Gempt; Bernhard Meyer
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

6.  Percutaneous transforaminal endoscopic decompression combined with percutaneous vertebroplasty in treatment of lumbar vertebral body metastases: A case report.

Authors:  Qiang Ran; Tong Li; Zhi-Ping Kuang; Xiao-Hong Guo
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.